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Abstract
Background: Timely diagnosis of the serious skin cancer melanoma can improve patient outcomes.
Clinical guidelines suggest that GPs use checklists, such as the 7-point checklist (7PCL), to assess
pigmented lesions. In 2016, the 7PCL was disseminated by EMIS as an electronic clinical decision
support (eCDS) tool.
Aim: To understand GP and patient perspectives on the implementation and usefulness of the
eCDS.
Design & setting: Semi-structured interviews with GPs and patients were undertaken. The
interviews took place in four general practices in the south east of England following consultations
using the eCDS for suspicious pigmented lesions.
Method: Data were collected from semi-structured face-to-face interviews with GPs and from
telephone interviews with patients. They were recorded and transcribed verbatim. The
Consolidated Framework for Implementation Research (CFIR) underpinned the analysis using
thematic approaches.
Results: A total of 14 interviews with GPs and 14 interviews with patients were undertaken. Most
GPs reported that, as the eCDS was embedded in the medical record, it was useful, easy to use,
time-efficient, and could facilitate patient–GP communication. They were less clear that it could
meet policy or patient needs to improve early diagnosis, and some felt that it could lead to
unnecessary referrals. Few felt that it had been sufficiently implemented at practice level. More felt
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confident with their own management of moles, and that the eCDS could be most useful for
borderline decision-making. No patients were aware that the eCDS had been used during their
consultation.
Conclusion: Successful implementation of a new tool, such as eCDS for melanoma, requires GPs to
perceive its value and understand how it can best be integrated into clinical practice. Disseminating
a tool without such explanations is unlikely to promote its adoption into routine practice.
How this fits in
Clinical decision support tools have the potential to help identify people at risk of cancer for early
referral and investigation, but there is little research evidence to guide their integration into clinical
software. This qualitative interview study with GPs and patients found that, compared with a paper
version, GPs viewed an embedded eCDS tool for suspicious pigmented lesions as easier to use,
time-efficient, and having the potential improve communication in the consultation. Some felt that it
could be more useful for borderline lesions but could lead to unnecessary referrals. These findings
can support implementation of eCDS tools for melanoma and other cancers into routine clinical
practice.
Introduction
Melanoma is the leading cause of skin cancer deaths in the UK, causing 2285 deaths in 2016.1 It is
associated with significant morbidity, and the thickness of the lesion at diagnosis is the most impor-
tant prognostic factor; for example, stage 1 disease has 5-year survival rates of >95%, compared
with 8% for males and 25% for females with stage 4 disease.2 Emerging evidence suggests that
opportunities to diagnose cancer earlier in primary care may be missed owing to failure to consider
the diagnosis, investigate it, or refer appropriately.3,4 Therefore, improving approaches to clinical
assessment and management of patients with potential skin cancer could improve their diagnostic
experiences and outcomes.5 In the NHS and similar healthcare systems, primary care is the first point
of contact for most patients worried about a skin change. Diagnosing relatively rare conditions such
as melanoma in primary care is challenging. This is because similar symptoms and signs are com-
monly presented and usually caused by benign conditions such as seborrheic keratoses and benign
naevi.
Clinical decision support (CDS) tools have the potential to help identify patients at risk of cancer
for early referral and investigation.6–8 However, while the aim of giving GPs tools to help them iden-
tify people with symptoms suspicious of cancer sooner is recommended by the National Institute for
Health and Care Excellence (NICE),9 there is currently no clinical trial evidence to support their inte-
gration into clinical software, despite widespread dissemination in England.10,11 A common problem
in the NHS is the introduction of change without sufficient piloting and attention to implementation,
and there is little evidence of how cancer tools are used, their safety, any harms that may occur for
patients and their GPs, and whether they have any positive impact on outcomes for patients.12 Fea-
sibility and qualitative studies examining non-electronic6,13 and electronic14 forms of cancer CDS
tools, and set in English primary care, demonstrated GP concerns about increased patient anxiety
and inappropriate referrals, despite an increase in cancer diagnostic activity, urgent referrals, and
cancer diagnoses.
Computerised symptom checklists may be easier to implement than more sophisticated cancer
decision support tools such as QCancer. For suspicious pigmented lesions, the NICE guidelines for
suspected cancer recommend GPs take a history and undertake naked-eye examination guided by
the weighted 7PCL.8 This checklist consists of three major features (scoring 2 points each): change in
size; irregular shape; and irregular colour. It also consists of four minor features (scoring 1 point
each): diameter greater than 7mm; inflammation; oozing; and change in sensation. The paper ver-
sion of the 7PCL has been validated as a diagnostic aid for pigmented skin lesions in general prac-
tice,15 and the authors’ randomised control trial evidence showed that GPs using it systematically
can manage patients presenting with suspicious pigmented lesions safely and effectively.16 In mid-
2016, an electronic version of the 7PCL was disseminated in a routine upload by a leading GP clinical
system (EMIS) to more than 50% of UK GPs17 as an eCDS for melanoma (see Figure 1). In this study,
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the use of this eCDS for melanoma in routine primary care was explored qualitatively. The aim was
to understand GP and patient perspectives on the implementation and usefulness of the melanoma
eCDS compared with the paper version.
Method
Participants and study design
Two clinical research networks (CRNs) approached EMIS-using general practices. Four agreed to
participate, and their GPs were reminded of where to locate the melanoma eCDS in their EMIS soft-
ware. GPs were purposively sampled to ensure maximum variation in age, sex, years of experience,
and teaching experience. Six to 8 weeks later, the researcher visited each practice to conduct inter-
views with these GPs.
Figure 1. Screenshots of EMIS software to show electronic clinical decision support for melanoma. eCDS = electronic clinical decision support.
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During this visit the electronic health records were searched to identify all the practice patients
who had presented with a skin lesion during the same time period and had the melanoma eCDS
used during their consultation. Again, they were purposively sampled to ensure maximum variation
in age, sex, and dermatology referral. If deemed eligible by their GP, patients were mailed study
invitation packs, and invited to respond directly to the research team if they agreed to take part in
an interview. Written informed consent was gained from the relevant GP or patient participant
before the start of each interview.
Data collection
In-depth semi-structured interviews were used to collect patient and GP views. Interviews were con-
ducted face-to-face with GPs, and by telephone with patients. Development of the interview sched-
ules was supported by literature searches and the expertise of the clinician team members. The
patient representative member of the research team reviewed both the GP and patient interview
schedules and made helpful improvements. The GP interview schedule explored introduction and
engagement with the eCDS; general issues about melanoma diagnosis; and strategies around eCDS
implementation. The patient interview schedule explored use of the eCDS tool within the consulta-
tion; patient recall of the use of the tool; perceptions about quality of care; and outcome of consul-
tation, including any subsequent follow-up. All interviews were conducted by an experienced
researcher, audio-recorded, professionally transcribed verbatim, and anonymised. GP interviews
lasted 26 minutes (mean; range 16–36 minutes), while patient interviews lasted 16 minutes (mean;
range 10–24 minutes).
Data analysis
The GP data were initially coded and categorised using a thematic approach to identify patterns or
themes within the interview data.18 One researcher read each transcript several times, and coding
began after familiarisation with the data. Descriptive themes were produced inductively based on
the data. Most of the transcripts were also read by the clinical researchers, and this core research
team met regularly to group the data into higher-level analytical themes, and to resolve any incon-
gruences arising from the coding. As the thematic analysis progressed, the process was also
informed by the CFIR, a model including five domains and further subthemes that affect the likeli-
hood of an innovation being incorporated into routine clinical care.19 CFIR was developed from a
meta-review of 12 systematic reviews, finding evidence for the domains and themes in the context
of implementing clinical guidelines.20 The use of an iterative process was continued to sort the
themes within the five main CFIR domains (see Figure 2); disconfirming data were also sought
throughout.21
The patient data were summarised, but further themetatic analysis was deemed inappropriate
due to the universal lack of awareness of the use of the melanoma eCDS during their consultations.
The data transcripts were organised and coded in NVivo (version 11). The presented quotations
from the findings are the richest examples of the finalised analytical themes. GP quotations are
accompanied by their sex and age, and patient quotations are accompanied by their sex, age, and
whether the patient was referred to specialist care.
Results
Participant characteristics
Between August 2016–January 2017, 14 interviews were completed with GPs (9 female; mean age
44 years [range 27–60]; mean experience 17 years [range 1–33]), and 14 interviews with patients (11
female; mean age 63 years, [range 36–80]), six of whom were referred to a specialist. Characteristics
of participating GPs and patients are presented in Table 1.
GP perspectives
GPs’ reflections could be mapped to all five domains of the CFIR, although most discussions focused
on the intervention characteristics, outer setting, and individual characteristics (see Figure 2). Some
quotations covered multiple themes within the CFIR framework, and therefore may be reported
more than once.
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1. Intervention characteristics
1.1 Strength and quality of evidence
The 2015 revised NICE guidelines for the management and referral of people with suspected cancer
featured in all the GP interviews, and most mentioned the guidance to use the 7PCL to assess a
mole. Several discussed how helpful it was when the 7PCL was integrated into 2-week wait urgent
referral forms. However, some were concerned about their legal position once they considered a
mole as a possible melanoma, and had used either the NICE guidelines or the melanoma eCDS:
’If that’s the NICE guidance and that’s in the CCG 2-week wait form, if you’ve got a score of 4
and you don’t refer, I think the lawyers would say that you’re not following guidance and they
could sue you.’ (F, 41–50 years)
1.2 Design quality
Most were familiar with using the melanoma eCDS and felt that it was clear, useful, and easy to use.
Some reflected on how using it did not intrude in a consultation, and that it could help with saving
time during or after a consultation:
’It’s simple to use and it’s on the referral form so it’s going to be easier to use it because then
you can put the score on the form, speed things up really.’ (F, 41–50 years)
’I think it’s more time-efficient because it’s tick, tick and you don’t have to sit there and write
"changed in size" and "changed in this" ...’ (F, 40 years)
Figure 2. Overview of the Consolidated Framework for Implementation Research as applied to eCDS tools. eCDS = electronic clinical decision support.
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Most mentioned particular features of the melanoma eCDS that appealed to them or they found
helpful, such as how it facilitated patient–GP communication in the consultation, and the ability to
draw the shape and size of the lesion:
’. . . quite funky with the drawing ability on it’ (M, 51 years).
Some GPs reflected on how to improve the usefulness of the tool, including the addition of a
pop-up prompt on the screen and a photograph for the clinical records:
’I suppose the prompt of a photo to be added would be helpful if they need to look through
it . . .’ (M, 40 years)
Some compared the melanoma eCDS favourably with other CDS systems:
’It’s a lot simpler and quicker than QCancer. I’ve only used the QCancer once — I probably
ought to have used it more, but it’s too long-winded to get your head around.’ (M, 51 years)
Several felt that expected features, such as family history or sun exposure, were missing, and a
few felt that the melanoma eCDS was too simple and not useful:
’I’m just concerned that it doesn’t ask about other things which are important, because maybe I
would even refer a person who scores three, but has a lot of exposure [or a] strong family
history.’ (F, 41–50 years)
2. Outer setting (outside the GP practice)
2.1 Patient needs and resources
Most GPs acknowledged patient concerns about possible melanoma and their wish for safe and
accurate assessment in primary care, and rapid referral and diagnosis if the lesion appeared
suspicious:
’I think [patients are] very clued up on moles changes, skin cancer.’ (F, 40 years)
Table 1A Characteristics of the participant GPs (n = 14)
n (%)
Age
Mean age, years (range) 44 (27–60)
40 years 5 (36)
41–50 years 4 (29)





White British 11 (79)
Asian British 1 (7)
Mixed 1 (7)
Other ethnic group 1 (7)
Years since qualification
Mean number of years (range) 17 (0–33)
5 years 5 (36)
6–25 years 5 (36)
26 years 4 (29)
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2.2 External policy and incentives
Most GPs were positive about policy approaches to improve early diagnosis of all cancers in general,
as well as melanoma in particular, but a few voiced doubts over the impact of early diagnosis on clin-
ical outcomes:
’Obviously it’s something to be encouraged, because if caught early then you’re going to
prevent something that could become a lot more serious. The difficulty is we see an awful lot of
pigmented lesions ... I’m aware that the diagnosis of [melanoma] has gone up, whereas the
overall mortality from it has not, and perhaps giving people a cancer diagnosis earlier, [may
have] no impact on their overall outcome.’ (M, 40 years)
However, almost all the GPs expressed concerns that using the melanoma eCDS could lead to
increased or unnecessary referrals, and were worried about the impact on specialist care. At the
same time, many acknowledged that more referrals could lead to more diagnoses:
’The danger is if we start referring too many people and they all turn out not to have melanoma,
then actually we’ve clogged up the system and it’s more difficult for people who do have to be
seen. But the counterargument is it may be that more people need to be seen to be picking up
some extra cases.’ (M, 40 years)
Many GPs discussed the advantages of the urgent referral pathways, and some highlighted effi-
cient local referral routes:
’There’s really good systems in place if you’re concerned about something, the 2-week wait
systems work efficiently, we’ve got a good referral form . . . we’ve got good support with the
email photo system . . . and we get a reply back from the consultant within 24 hours, to say "yes
it’s fine [or] refer them".’ (F, 41–50 years)
3. Inner setting (within the GP practice)
3.1 Implementation climate
No GPs recollected any practice discussions about whether they should implement the melanoma
eCDS, or how its use would be supported:
‘It just appeared in EMIS’ (M, >51 years).
Furthermore, there were no discussions around how GP colleagues could support its use. A few
considered whether people other than GPs, such as practices nurses or non-clinical staff, could safely
use the melanoma eCDS. Although they were felt to be technically capable, it was generally felt that
a GP needed to make the clinical decision:
’[Practice nurses] haven’t done the training and they haven’t done the years of looking at skin
lesions that we get every day.’ (M, 51 years)
4. Individual characteristics: knowledge, attitudes, self-efficacy, and other
personal attributes
Most GPs were familiar with using the melanoma eCDS and felt that it was clear, useful, and easy to
use. Some reflected on how it did not intrude in a consultation, and that it could help with saving
time. There was a range of views about whether using the eCDS was of more value during the con-
sultation to help with decision-making, or after the consultation for record-keeping, referral, and to
confirm their management decision:
’Without the checklist I already know what to look for. I know that if it’s changed in size, if it’s
irregular, that those are all serious ... So I would have already gone through it anyway, with or
without the [list] in front of me, so does it really matter? Probably not. It’s in my head like any
other medical problem, I mean, I consult all day long.’ (F, 41–50 years)
The GPs mainly felt that the melanoma eCDS was most useful for borderline decision-making:
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’My experience has been the scores have either been 5 or 6, or 1, and not much in the middle,
so you either will or you won’t [refer] . . . if there are lesions that score 2 or 3 or 4, that’s going to
be the grey area where actually it might help.’ (F, 40 years)
They also felt that it could be more useful for less experienced GPs or those who felt less confi-
dent when examining skin lesions:
’I think that’s right for those . . . certainly trainees, and maybe younger GPs and people who
haven’t done a lot of dermatology, yeah.’ (M, 51 years)
Some discussed using the melanoma eCDS for reassurance, either for themselves or for their
patient:
’. . . if someone was very worried and they scored zero then I might be able to say, “Look, this is
a scoring system that’s been developed,” and it might just aid reassurance. Equally, if I was
worried about someone and I wanted to explain why, I might just say, “Look, this is the scoring
system, you’ve got quite a lot of points on this. It doesn’t mean it’s anything serious but it does
mean we need to look into it more closely".’ (M, 40 years)
However, GPs were keen to discuss the importance of their clinical expertise and knowledge of
their patients, and how they placed more value on their clinical judgment than the melanoma eCDS:
’Our clinical knowledge still has to come through, you know, and it has to be tailored to
individuals ...’ (F, 41–50 years)
’I’ve referred ones that didn’t score very highly. I’ve not referred ones that did score highly. I
think they are helpful but I wouldn’t tie myself to them entirely.’ (M, 40 years)
Indeed, some showed clear antipathy to any form of guideline or checklist:
‘ ... checklists are for robots.’ (F, 41–50 years).
’I think the downside of . . . making everything a tick-box exercise, does take away your clinical
judgment, you can deskill. I don’t think that’s such a risk with this actually.’ (M, 40 years)
This appeared to be owing to the firmly held mental models for triaging patients’ symptoms and
signs:
’I think most GPs. . . . we are checklist people in our head, that’s what we’re trained to do and
we would quite naturally tell the patient, “I think these are important, or these are not




Most GPs discussed a lack of clear implementation strategies for guidelines and IT tools in their
practice. Therefore, few felt that they had been made aware of it:
’It may be that we [partners] just decide by email . . . Now it might probably go to the IT hub to
decide on whether we should use it. But on the whole when these things arrive I think they tend
to just get installed, especially something like templates which don’t force itself on you. You can
still choose to make use of it. But the problem I had with that, we weren’t made aware of it.’ (M,
40 years)
5.2 Reflecting and evaluating
There were no GPs or practices in this study that regularly monitored the impact on their referrals of
using the eCDS or any other type of evaluation of impact. Some GPs reflected on how to improve
the usefulness of the tool.
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Patient perspectives
The patients were universally unaware that the melanoma eCDS had been used during their consul-
tation about a concerning pigmented lesion.
Table 2 contains illustrative quotations from each patient about their consultation, including
whether they were examined, whether a checklist or computer tool was used, and whether they
were referred. In summary, all the patients described their examination in detail, with half reporting
that their GP had used a magnifying glass or dermatoscope to examine their skin. None recalled a
checklist being used during the consultation, and most were very confident about this. Less than a
third reported that the GP used a computer during their consultation, and all felt that this was for
general data entry rather than for specific use of an electronic tool.
Discussion
Summary
In this qualitative investigation, the English GPs in the sample reported that, as the eCDS for mela-
noma was embedded in the electronic medical record, it was easy to use in routine clinical care,
time-efficient, most useful for borderline clinical decision-making, could facilitate patient–GP com-
munication in the consultation, and might improve timely diagnosis of melanoma and patient experi-
ences. However, GPs were concerned that melanoma eCDS could lead to increased or unnecessary
referrals to specialist care, and felt that better implementation could enhance its uptake and useful-
ness. Surprisingly, none of the 14 patients who were interviewed were aware that the melanoma
Table 1B Characteristics of the participant patients (n = 14)
n (%)
Age
Mean age, years (range) 63 (36–80)
<60 years 5 (36)
60–69 years 4 (29)





White British 14 (100)
Highest qualification
None 2 (14)
GCSE equivalent 7 (50)
A-level 1 (7)








Referral to a specialist 6 (43)
No further action 8 (57)
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Table 2. Illustrative quotations from each patient about their consultation, including whether they were examined, whether a checklist or computer
tool was used, and whether they were referred.
Patient
ID, sex,






’A junior doctor, she took some notes and
she thought it was probably one of those
keratosey things . . . she’d had a look
through one of those little glass things that
they put up, and she thought it was
probably okay . . . Dr A came in to check
what she’d said to me, he couldn’t look
through one of those things and, because
of my history, that’s why he sent me up’
’I don’t remember that, no’ ’Yeah, she looked at it, asked me
questions, I don’t remember them being
questions on computer, it was more why





’She measured the dark brown marks and
she looked at the others and said, “Yes, it
had cleared up”’
’No’ ’No, only to look up because she wasn’t the
one who started the tablets off, to see how






’Yeah, she did . . . as I recall she looked at it,
and then I think she just stretched the skin a
little bit by it, you know, put her finger
either side of it and just pulled it like that
and looked at it again and . . . well I don’t
think she asked me if I’d got any problems
anywhere else, she just sort of felt my arms
and then she said, “Well I think the best
thing is to. . . get a specialist to look at it”’




’He took a photo and he looked at it, you
know, with a sort of glass and he said "Well
I think it’s a small growth" and . . . I can’t
think what happened then... "We’ll have to
keep an eye on it", I think that’s what he
said’
’No, no.’ ’Sometimes you can go there and see one
and he never looks at you at all and he just
types, but this one, he did sit and look at it,











’I obviously explained why I was there and
that I’d been before and when, and
he . . . tracked it down on a computer and
found his notes from the previous
consultation. And then he looked at it with
a magnifying glass and he measured it and
he . . . asked me if it was painful and if it was
itchy and I’d already told him that I wasn’t
sure but I thought it might have changed
colour a bit and got a bit bigger’
’Right, well, I’m not aware of him using a
specific tool, if . . . you’re really looking at
the effectiveness of this tool’
’Yeah, he did use the computer during the
consultation but they always do, don’t
they? It didn’t seem that he used it any





’She had look at it and I think, I explained
my history because I hadn’t seen this lady
with my previous back thing, so she read
the notes’
’No, I don’t remember that, no, we just





’I asked her just to check them, so she had
a look and she said they look absolutely
fine, they do just naturally grow but she
didn’t have any concerns with them at
all . . . I think, yeah, just with her own eyes. I
was going to say did she measure them but
I don’t think she did. No, ’cos I really don’t





’Well, I just took my top off and she
checked it, and then got, I know she looked
through whatever it is they look through
with their light or whatever, I don’t know
what it’s called’
’Not really, no I don’t think so . . . to be
honest I can’t remember, but I don’t think
so.’
’No’ N
Table 2 continued on next page
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eCDS had been used during their consultation with their GP, despite half being referred for a suspi-
cious lesion and many GPs expressing the view that the melanoma eCDS could have most value
when supporting borderline decision-making.
Strengths and limitations
This is the first time that routine use in primary care of any electronic checklist or CDS tool for mela-
noma has been evaluated. The adoption of the widely used and rigorously developed CFIR
model was chosen to support the analysis. This is the first time that it has been applied to an evalua-
tion of an electronic checklist or CDS for possible cancer in the primary care setting, and it enabled
the areas of improvement necessary to increase routine adoption of the eCDS for melanoma to be
highlighted. Most of the GP interview data could be mapped onto the five domains of the CFIR
model, although there were meagre data relating to the inner setting (implementation climate) or
the implementation process. This was likely owing to the lack of explicit implementation by the com-
puter software provider or the general practice managers. Nevertheless, uptake was probably better
than expected owing to the melanoma eCDS simply being an electronic version of the NICE-recom-
mended 7PCL, albeit with the addition of a drawing tool, enabling GPs to more accurately record
the location of the lesion on their patient’s body. Using the CFIR model enabled these subtle distinc-
tions to be drawn.
A further strength is that the GPs and patients were recruited from four general practices located
across two CRNs in order to collect as wide a range of views as possible. Although there were more










’She looked at it by rubbing some funny gel
on it and putting like a spy glass on it, I’m
sure you’re familiar with that, I suspect it
just aids the visibility. She informed me at
that time that it was nothing problematic
but offered to whip it off with some freezy
spray next time I was in . . .’
’I don’t recall her looking at any, she didn’t
give me any check sheets or computer
stuff, no’




’He looked at it with a magnifying light and
he did study it, yes, and I think he probably
asked me how long I’d looked at it’




’I showed her and she had a look at it, she
measured it with a little tool thing and she
said she really couldn’t see anything wrong
with it ... I think she just measured it. It was
a sort of a measuring device’
’No, no. I don’t think there was any need





’I just explained the background, I said
something about what was there and she
had a look at it, and we spent enough time
I felt with it, I was quite satisfied and I’m not
sure what instrument she looked at it
through, it was just a little black handheld
thing that, you know, she looked at it very
closely’
’No, no, because that wasn’t the main
thing I was really going there about so I
guess she was running out of time too, but





’She had a look at them, she said there was
only one that might possibly be and so the
point of taking a photograph was to see if it
got bigger because . . . that would be a
sign that there might be something to
worry about . . . We’ve done two further
checks when I’ve been there for something
else and both times she thought it hadn’t
got bigger, this particular one that she’s
keeping her eye on and photographing’
’No I’m quite sure she didn’t’ n/a N
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years in practice. It is possible that sex influenced attitudes towards the melanoma eCDS. Other limi-
tations include the recruitment from only central and eastern England, and that patients were
unaware of the eCDS use during their consultations. It is not clear whether the findings generalise to
general practices, GPs and patients not involved in this research, or to those not using EMIS soft-
ware. Also, the participating GPs may have held more extreme views than most GPs, being either
more or less likely to have experienced implementation issues with the melanoma eCDS.
Comparison with existing literature
CDS has been used in primary care for a range of acute and chronic conditions such as new-onset
chest pain.22 It is also beginning to be used to support cancer screening23 and treatment decision-
making. Few studies have examined the in-practice use of CDS to diagnose cancer earlier, although
a randomised controlled trial set in English general practice is currently evaluating an eCDS tool for
assessing upper gastrointestinal symptoms that could indicate cancer.10 One qualitative study
explored English GPs’ experiences after embedding eCDS tools for suspected lung or colorectal
cancer in primary care, and found them to be useful additions despite issues with ’prompt fatigue’.14
There have been more experimental primary care studies. In England, one examined the impact of a
diagnostic decision support system on the consultation, and found that GPs felt that it changed their
consultation style, by requiring them to code symptoms and signs while interacting with the patient,
while patients sometimes commented that GPs were looking at their computer more than at them.24
Another study, using simulated consultations with Australian GPs to explore implementing a
QCancer risk tool into general practice consultations, had similar findings; however, significant bar-
riers were also found, most notably when the tool outcome and the experienced GP’s clinical judg-
ment were not in line.25
Implications for practice
A recent analysis of cancer registry data suggests, for the first time, that GP use of CDS may affect
cancer outcomes as melanomas are thinner at diagnosis when referred by GPs with this eCDS
embedded in their software compared with GPs without the eCDS embedded (Barclay M, et al,
unpublished data, 2019). Therefore, there are two key implications from this study. First, while there
is policy enthusiasm for integrating clinical decision rules into electronic health records, there are
unanswered questions relating to the implementation and uptake of cancer eCDS in primary care
settings. Successful implementation of a new tool, such as this melanoma eCDS, requires GPs to
understand its value and how it can best be integrated into routine clinical practice. This study shows
that this process needs to proceed with caution, and a great deal of attention needs to be
tailored to implementation. These strategies are more likely to optimise implementation and equita-
ble uptake by clinicians and patients alike. This is reflected in the literature; for example, while a sys-
tematic review of patient safety strategies targeted at reducing diagnostic errors by primary care
clinicians found the strongest evidence for technology-based interventions, such as computer-
assisted diagnostic aids and decision support algorithms,26 challenges to implementing the more
widely used cardiovascular risk assessment tools were described.27 A recent review on risk predic-
tion tools for cancer (for example, QCancer and risk assessment tools) found that, although there is
a potential for clinical use, usability in the clinic by GPs and by patients at home is not well
researched.28
Second, the 7PCL is already widely used by English GPs as a paper or ‘mental’ version. This study
evaluated the use of an electronic version of the checklist rather than a more sophisticated algo-
rithm-driven tool like QCancer, and found it to be useful, particularly for ‘borderline’ lesions. This is
likely to have been owing to the immediate accessibility of the embedded eCDS in the medical
records. While other technological approaches to help GPs assess skin changes or pigmented skin
lesions, such as dermoscopy, are increasingly available, they currently lack evidence for their accu-
racy, safety, acceptability to clinicians and patients, and cost-effectiveness in the primary care set-
ting. For these new technological approaches to reach their potential, proven (evidence-based)
tailored implementation is of the highest importance.
In summary, most GPs in this study were familiar with the melanoma eCDS and felt that, com-
pared with the paper version, it was easier to use, time-efficient, and could improve communication
in the consultation. They were less clear that it could meet policy or patient needs to improve early
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diagnosis, and some felt that it could lead to unnecessary referrals. Few felt that it had been suffi-
ciently implemented at practice level. More felt confident with their own management of moles, and
that the eCDS could be most useful for borderline decision-making. For implementation to be suc-
cessful, it should involve more than just installing new software on GPs’ computers overnight.
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